Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Other Non-Current Liabilities data on record, last reported at $5.2 million in Q3 2022.

  • For Q3 2022, Other Non-Current Liabilities changed N/A year-over-year to $5.2 million; the TTM value through Sep 2022 reached $5.2 million, changed N/A, while the annual FY2021 figure was $5.9 million, 16377.78% up from the prior year.
  • Other Non-Current Liabilities reached $5.2 million in Q3 2022 per AVIR's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $6.0 million in Q2 2022 and bottomed at $29000.0 in Q2 2021.
  • Average Other Non-Current Liabilities over 3 years is $2.9 million, with a median of $2.6 million recorded in 2021.
  • The widest YoY moves for Other Non-Current Liabilities: up 20617.24% in 2022, down 5149.56% in 2022.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $36000.0 in 2020, then skyrocketed by 16377.78% to $5.9 million in 2021, then fell by 12.85% to $5.2 million in 2022.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $5.2 million in Q3 2022, $6.0 million in Q2 2022, and $5.9 million in Q1 2022.